Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003520 · ClinicalTrials.gov registry record · Phase 2
Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
A Phase 2 study, sponsored by Burzynski Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00003520 is a Phase 2 study that was terminated before completion, run by Burzynski Research Institute. The registered enrollment target is 15 participants.
The verdict
NCT00003520, a Phase 2 study, was terminated before completion, sponsored by Burzynski Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Current therapies for Stage IV Kidney Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Kidney Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV Kidney Cancer.
Interventions
- DRUG Antineoplaston therapy (Atengenal + Astugenal)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1996-03-27 |
| Est. Completion | 2005-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003520
The ClinicalTrials.gov registry entry for NCT00003520 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Burzynski Research Institute, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antineoplaston therapy (Atengenal + Astugenal) is the first listed.
NCT00003520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003520 about?
NCT00003520 is a clinical study titled "Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer". Current therapies for Stage IV Kidney Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Kidney Cancer. PURPOSE: This study is being performed to determine the effects (good and b...
What is the current status of trial NCT00003520?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 1996-03-27. Estimated completion is 2005-01-23.
What interventions are being tested in trial NCT00003520?
The interventions under investigation include: Antineoplaston therapy (Atengenal + Astugenal) (DRUG).
Who is sponsoring clinical trial NCT00003520?
This trial is sponsored by Burzynski Research Institute, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.